Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies

Journal of Cardiovascular Magnetic Resonance

Volumn 14, Issue 1, 2012, Pages

  Parsai, Chirine ^a,b   Ohanlon, Rory ^a,c   Prasad, Sanjay K ^a,d   Mohiaddin, Raad H ^a,d  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b Polyclinique les Fleurs   (France)

^c Blackrock Clinic Ireland   (Ireland)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CHAGAS DISEASE; CHEMOTHERAPY INDUCED CARDIOMYOPATHY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FABRY DISEASE; GRAFT REJECTION; HEART AMYLOIDOSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HEART RIGHT VENTRICLE DYSPLASIA; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART VENTRICLE VOLUME; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMAGE QUALITY; IN VIVO STUDY; IRON OVERLOAD CARDIOMYOPATHY; LATE GADOLINIUM ENHANCEMENT; MYOCARDIAL PERFUSION IMAGING; MYOCARDITIS; NON ISCHEMIC CARDIOMYOPATHY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REPRODUCIBILITY; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TAKOTSUBO CARDIOMYOPATHY; THORAX PAIN; VENTRICULAR NONCOMPACTION;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MYOCARDIUM; PROGNOSIS;

EID: 84864442229     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-14-54     Document Type: Review

References (145)

1. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB, Circulation 2006 113 1807 1816 10.1161/CIRCULATIONAHA.106. 174287 16567565
2. ACUT2E TSE-SSFP: a hybrid method for T2-weighted imaging of edema in the heart. Aletras AH, Kellman P, Derbyshire JA, Arai AE, Magn Reson Med 2008 59 229 235 10.1002/mrm.21490 18228588
3. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, et al. Eur Heart J 2008 29 270 276 17916581
4. Role of Cardiovascular Magnetic Resonance as a Gatekeeper to Invasive Coronary Angiography in Patients Presenting With Heart Failure of Unknown Etiology. Assomull RG, Shakespeare C, Kalra PR, Lloyd G, Gulati A, Strange J, Bradlow WM, Lyne J, Keegan J, Poole-Wilson P, et al. Circulation 2011 124 1351 1360 10.1161/CIRCULATIONAHA.110.011346 21900085
5. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E, Journal of Cardiovascular Magnetic Resonance 2008 10 35 10.1186/1532-429X-10-35 18605997
6. Society for Cardiovascular Magnetic Resonance guidelines for reporting cardiovascular magnetic resonance examinations. Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA, McConnell MV, Raman SV, van Rossum AC, Flamm S, Kramer CM, Nagel E, Neubauer S, Journal of Cardiovascular Magnetic Resonance 2009 11 5 10.1186/1532-429X-11-5 19257889
7. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Moon JC, Fisher NG, McKenna WJ, Pennell DJ, Heart 2004 90 645 649 10.1136/hrt.2003.014969 15145868
8. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E, J Cardiovasc Magn Reson 2008 10 35 10.1186/1532-429X-10-35 18605997
9. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Pennell DJ, Sechtem UP, Higgins CB, Manning WJ, Pohost GM, Rademakers FE, van Rossum AC, Shaw LJ, Yucel EK, Eur Heart J 2004 25 1940 1965 10.1016/j.ehj.2004.06.040 15522474
10. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. Maceira AM, Prasad SK, Khan M, Pennell DJ, J Cardiovasc Magn Reson 2006 8 417 426 10.1080/ 10976640600572889 16755827
11. The future of real-time cardiac magnetic resonance imaging. Nayak KS, Hu BS, Curr Cardiol Rep 2005 7 45 51 10.1007/s11886-005-0010-x 15610648
12. Comparison of magnetic resonance real-time imaging of left ventricular function with conventional magnetic resonance imaging and echocardiography. Schalla S, Nagel E, Lehmkuhl H, Klein C, Bornstedt A, Schnackenburg B, Schneider U, Fleck E, Am J Cardiol 2001 87 95 99 10.1016/S0002-9149(00)01279-0 11137841
13. Magnetic resonance real-time imaging for the evaluation of left ventricular function. Nagel E, Schneider U, Schalla S, Ibrahim T, Schnackenburg B, Bornstedt A, Klein C, Lehmkuhl HB, Fleck E, J Cardiovasc Magn Reson 2000 2 7 14 10.3109/10976640009148668 11545110
14. Nuclear magnetic resonance imaging of acute myocardial infarction in dogs: alterations in magnetic relaxation times. Higgins CB, Herfkens R, Lipton MJ, Sievers R, Sheldon P, Kaufman L, Crooks LE, Am J Cardiol 1983 52 184 188 10.1016/0002-9149(83)90093-0 6858909
15. Myocardial edema - a new clinical entity? Friedrich MG, Nat Rev Cardiol 2010 7 292 296 20309007
16. T2-weighted cardiovascular magnetic resonance in acute cardiac disease. Eitel I, Friedrich MG, J Cardiovasc Magn Reson 2011 13 13 10.1186/1532-429X-13- 13 21332972
17. Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches. Abdel-Aty H, Boye P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D, Bock P, Dietz R, Friedrich MG, Schulz-Menger J, J Am Coll Cardiol 2005 45 1815 1822 10.1016/j.jacc.2004.11.069 15936612
18. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H, Gutberlet M, Prasad S, et al. J Am Coll Cardiol 2009 53 1475 1487 10.1016/j.jacc.2009.02.007 19389557
19. Myocardial edema is a feature of Tako-Tsubo cardiomyopathy and is related to the severity of systolic dysfunction: insights from T2-weighted cardiovascular magnetic resonance. Abdel-Aty H, Cocker M, Friedrich MG, Int J Cardiol 2009 132 291 293 10.1016/j.ijcard.2007.08.102 18086501
20. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: a review. Butler CR, Thompson R, Haykowsky M, Toma M, Paterson I, J Cardiovasc Magn Reson 2009 11 7 10.1186/1532-429X-11-7 19284612
21. Using magnetic resonance imaging to characterize recent myocardial injury: utility in acute coronary syndrome and other clinical scenarios. Arai AE, Circulation 2008 118 795 796 10.1161/CIRCULATIONAHA.108.797373 18711021
22. Myocardial salvage: retrospection, resolution, and radio waves. Pennell D, Circulation 2006 113 1821 1823 10.1161/CIRCULATIONAHA.105.618942 16618830
23. Single-shot steady-state free precession can detect myocardial edema in patients: a feasibility study. Green JD, Clarke JR, Flewitt JA, Friedrich MG, J Magn Reson Imaging 2009 30 690 695 10.1002/jmri.21868 19634173
24. Direct t2 quantification of myocardial edema in acute ischemic injury. Verhaert D, Thavendiranathan P, Giri S, Mihai G, Rajagopalan S, Simonetti OP, Raman SV, JACC Cardiovasc Imaging 2011 4 269 278 10.1016/j.jcmg.2010.09.023 21414575
25. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ, Eur Heart J 2001 22 2171 2179 10.1053/euhj.2001.2822 11913479
26. ACCF/ACR/SCCT/SCMR/ASNC/NASCI/SCAI/SIR 2006 appropriateness criteria for cardiac computed tomography and cardiac magnetic resonance imaging: a report of the American College of Cardiology Foundation Quality Strategic Directions Committee Appropriateness Criteria Working Group, American College of Radiology, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, American Society of Nuclear Cardiology, North American Society for Cardiac Imaging, Society for Cardiovascular Angiography and Interventions, and Society of Interventional Radiology. Hendel RC, Patel MR, Kramer CM, Poon M, Carr JC, Gerstad NA, Gillam LD, Hodgson JM, Kim RJ, Lesser JR, et al. J Am Coll Cardiol 2006 48 1475 1497 10.1016/j.jacc.2006.07.003 17010819
27. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA, Selvanayagam JB, Neubauer S, Watkins H, Circulation 2007 115 2418 2425 10.1161/CIRCULATIONAHA. 106.657023 17452610
28. Optimization of fast cardiac imaging using an echo-train readout. Epstein FH, Arai AE, J Magn Reson Imaging 2000 11 75 80 10713937
29. Phase-sensitive inversion-recovery MR imaging in the detection of myocardial infarction. Huber AM, Schoenberg SO, Hayes C, Spannagl B, Engelmann MG, Franz WM, Reiser MF, Radiology 2005 237 854 860 10.1148/radiol.2373041483 16304107
30. Assessment of late gadolinium enhancement in nonischemic cardiomyopathy: comparison of a fast Phase-Sensitive Inversion Recovery Sequence (PSIR) and a conventional segmented 2D gradient echo recall (GRE) sequence - preliminary finding. Elgeti T, Abdel-Aty H, Wagner M, Busjahn A, Schulz-Menger J, Kivelitz D, Dietz R, Hamm B, Invest Radiol 2007 42 671 675 10.1097/RLI.0b013e3180661a95 17984763
31. Value of 2D phase sensitive inversion recovery (PSIR) in comparison to a 3D inversion recovery gradient echo sequence (IR-GRE) for the detection of myocardial scar by MRI in different myocardial diseases. Schindler KLC, Kösser A, Hoffmann J, Nitzsche S, Schnackenburg B, Schuler G, Thiele H, Gutberlet M, J Cardiovasc Magn Reson 2008 10 160
32. Head-to-head comparison of eight late gadolinium-enhanced cardiac MR (LGE CMR) sequences at 1.5 tesla: from bench to bedside. Viallon M, Jacquier A, Rotaru C, Delattre BM, Mewton N, Vincent F, Croisille P, J Magn Reson Imaging 2011 34 1374 1387 10.1002/jmri.22783 21972032
33. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Spiewak M, Malek LA, Misko J, Chojnowska L, Milosz B, Klopotowski M, Petryka J, Dabrowski M, Kepka C, Ruzyllo W, Eur J Radiol 2010 74 149 e153 10.1016/j.ejrad.2009.05.035 19523780
34. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, Webb J, Kulkarni M, Dawson D, Sulaibeekh L, et al. J Am Coll Cardiol 2010 56 867 874 10.1016/j.jacc.2010.05.010 20688032
35. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. Flett AS, Hasleton J, Cook C, Hausenloy D, Quarta G, Ariti C, Muthurangu V, Moon JC, JACC Cardiovasc Imaging 2011 4 150 156 10.1016/j.jcmg.2010.11.015 21329899
36. Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. de Leeuw N, Ruiter DJ, Balk AH, de Jonge N, Melchers WJ, Galama JM, Transpl Int 2001 14 299 306 11692213
37. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ, J Am Coll Cardiol 2008 52 1574 1580 10.1016/j.jacc.2008.06.049 19007595
38. Measurement of the gadopentetate dimeglumine partition coefficient in human myocardium in vivo: normal distribution and elevation in acute and chronic infarction. Flacke SJ, Fischer SE, Lorenz CH, Radiology 2001 218 703 710 11230643
39. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE, Am J Physiol Heart Circ Physiol 2008 295 1234 H1242 10.1152/ajpheart.00429.2008 18660445
40. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP, Magn Reson Med 2004 52 141 146 10.1002/mrm.20110 15236377
41. Myocardial T1 mapping: application to patients with acute and chronic myocardial infarction. Messroghli DR, Walters K, Plein S, Sparrow P, Friedrich MG, Ridgway JP, Sivananthan MU, Magn Reson Med 2007 58 34 40 10.1002/mrm.21272 17659622
42. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD, J Cardiovasc Magn Reson 2010 12 69 10.1186/1532-429X-12-69 21092095
43. Histological validation of ShMOLLI equilibrium contrast CMR for the measurement of diffuse myocardial fibrosis. White SK PS, Neubauer S, Robson MD, Moon J, J Cardiovasc Magn Reson 2012 14 suppl 1 111 10.1186/1532-429X-14-S1-O111
44. T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison. Gai N, Turkbey EB, Nazarian S, van der Geest RJ, Liu CY, Lima JA, Bluemke DA, Magn Reson Med 2010 65 1407 1415 21500267
45. Gadolinium-enhanced magnetic resonance imaging for detection and quantification of fibrosis in human myocardium in vitro. Kehr E, Sono M, Chugh SS, Jerosch-Herold M, Int J Cardiovasc Imaging 2008 24 61 68 17429755
46. Cardiovascular magnetic resonance imaging for valvular heart disease: technique and validation. Cawley PJ, Maki JH, Otto CM, Circulation 2009 119 468 478 10.1161/CIRCULATIONAHA.107.742486 19171869
47. Myocardial tagging by cardiovascular magnetic resonance: evolution of techniques - pulse sequences, analysis algorithms, and applications. el SH I, J Cardiovasc Magn Reson 2011 13 36 10.1186/1532-429X-13-36 21798021
48. Comparison of magnetic resonance feature tracking for strain calculation with harmonic phase imaging analysis. Hor KN, Gottliebson WM, Carson C, Wash E, Cnota J, Fleck R, Wansapura J, Klimeczek P, Al-Khalidi HR, Chung ES, et al. JACC Cardiovasc Imaging 2010 3 144 151 10.1016/j.jcmg.2009.11.006 20159640
49. Functional measurements based on feature tracking of cine magnetic resonance images identify left ventricular segments with myocardial scar. Maret E, Todt T, Brudin L, Nylander E, Swahn E, Ohlsson JL, Engvall JE, Cardiovasc Ultrasound 2009 7 53 10.1186/1476-7120-7-53 19917130
50. Cardiovascular magnetic resonance myocardial feature tracking detects quantitative wall motion during dobutamine stress. Schuster A, Kutty S, Padiyath A, Parish V, Gribben P, Danford DA, Makowski MR, Bigalke B, Beerbaum P, Nagel E, J Cardiovasc Magn Reson 2011 13 58 10.1186/1532-429X-13-58 21992220
51. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, et al. Circulation 2006 113 671 678 10.1161/CIRCULATIONAHA.105.580506 16461840
52. Nephrogenic systemic fibrosis: a concise review for cardiologists. Cheong BY, Muthupillai R, Tex Heart Inst J 2010 37 508 515 20978560
53. Assessment of left ventricular mass by cardiovascular magnetic resonance. Myerson SG, Bellenger NG, Pennell DJ, Hypertension 2002 39 750 755 10.1161/hy0302.104674 11897757
54. Telmisartan, ramipril, or both in patients at high risk for vascular events. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C, N Engl J Med 2008 358 1547 1559 18378520
55. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, Schulz-Menger J, J Am Coll Cardiol 2009 53 284 291 10.1016/j.jacc.2008.08.064 19147047
56. Myocardial delayed contrast enhancement in patients with arterial hypertension: initial results of cardiac MRI. Andersen K, Hennersdorf M, Cohnen M, Blondin D, Modder U, Poll LW, Eur J Radiol 2009 71 75 81 10.1016/j.ejrad. 2008.03.009 18434065
57. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, Donnelly SC, McDonald K, Circulation 2007 115 888 895 10.1161/CIRCULATIONAHA.106.638569 17283265
58. Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Kupari M, Turto H, Lommi J, Eur Heart J 2005 26 1790 1796 10.1093/eurheartj/ehi290 15860517
59. Quantification of valvular aortic stenosis by magnetic resonance imaging. Friedrich MG, Schulz-Menger J, Poetsch T, Pilz B, Uhlich F, Dietz R, Am Heart J 2002 144 329 334 10.1067/mhj.2002.124057 12177653
60. Magnetic resonance to assess the aortic valve area in aortic stenosis: how does it compare to current diagnostic standards? John AS, Dill T, Brandt RR, Rau M, Ricken W, Bachmann G, Hamm CW, J Am Coll Cardiol 2003 42 519 526 10.1016/S0735-1097(03)00707-1 12906983
61. Prognostic significance of myocardial fibrosis quantification by histopathology and magnetic resonance imaging in patients with severe aortic valve disease. Azevedo CF, Nigri M, Higuchi ML, Pomerantzeff PM, Spina GS, Sampaio RO, Tarasoutchi F, Grinberg M, Rochitte CE, J Am Coll Cardiol 2010 56 278 287 10.1016/j.jacc.2009.12.074 20633819
62. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Weidemann F, Herrmann S, Stork S, Niemann M, Frantz S, Lange V, Beer M, Gattenlohner S, Voelker W, Ertl G, Strotmann JM, Circulation 2009 120 577 584 10.1161/CIRCULATIONAHA.108.847772 19652094
63. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. Dweck MR, Joshi S, Murigu T, Alpendurada F, Jabbour A, Melina G, Banya W, Gulati A, Roussin I, Raza S, et al. J Am Coll Cardiol 2011 58 1271 1279 10.1016/j.jacc.2011.03.064 21903062
64. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC, Circulation 2010 122 138 144 10.1161/CIRCULATIONAHA.109.930636 20585010
65. Quantification of diffuse myocardial fibrosis and its association with myocardial dysfunction in congenital heart disease. Broberg CS, Chugh SS, Conklin C, Sahn DJ, Jerosch-Herold M, Circ Cardiovasc Imaging 2010 3 727 734 10.1161/CIRCIMAGING.108.842096 20855860
66. Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: comparison with 99mTc-DTPA autoradiography in rats. Arheden H, Saeed M, Higgins CB, Gao DW, Bremerich J, Wyttenbach R, Dae MW, Wendland MF, Radiology 1999 211 698 708 10352594
67. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, Kellman P, Jones BL, Ludwig DR, Schwartzman D, et al. J Cardiovasc Magn Reson 2011 13 16 10.1186/1532-429X-13-16 21375743
68. Hypertrophic cardiomyopathy phenotype revisited after 50years with cardiovascular magnetic resonance. Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, Olivotto I, Biller L, Lesser JR, Udelson JE, Manning WJ, Appelbaum E, J Am Coll Cardiol 2009 54 220 228 10.1016/j.jacc.2009.05.006 19589434
69. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, Lesser JR, Udelson JE, Ackerman MJ, Maron BJ, Circulation 2008 118 1541 1549 10.1161/CIRCULATIONAHA.108.781401 18809796
70. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging. Park JR, Choi JO, Han HJ, Chang SA, Park SJ, Lee SC, Choe YH, Park SW, Oh JK, Int J Cardiovasc Imaging 2011 28 763 772 21516440
71. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M, Lytle BW, Lever HM, Desai MY, J Am Coll Cardiol 2009 54 242 249 10.1016/j.jacc.2009.04.026 19589437
72. Usefulness of cardiac magnetic resonance in assessing the risk of ventricular arrhythmias and sudden death in patients with hypertrophic cardiomyopathy. Leonardi S, Raineri C, De Ferrari GM, Ghio S, Scelsi L, Pasotti M, Tagliani M, Valentini A, Dore R, Raisaro A, Arbustini E, Eur Heart J 2009 30 2003 2010 10.1093/eurheartj/ehp152 19474054
73. Hermans-van Ast JF, Snoep G, Alzand BS, Arens YH, van den Wijngaard A, Crijns HJ, Pinto YM: Exercise related ventricular arrhythmias are related to cardiac fibrosis in hypertrophic cardiomyopathy mutation carriers. van Rijsingen IA, Bekkers SC, Schalla S, Neth Heart J 2011 19 168 174 10.1007/s12471-011- 0090-8 21475680
74. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ, Circ Heart Fail 2008 1 184 191 10.1161/CIRCHEARTFAILURE.108.768119 19808288
75. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert EM, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H, J Am Coll Cardiol 2010 56 875 887 10.1016/j.jacc.2010.05.007 20667520
76. Abstract 4187: Identification of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging as a Major Risk Factor for Sudden Death in Hypertrophic Cardiomyopathy. Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Tajik AJ, Gersh BJ, Circulation 2008 118 -839
77. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. Maron BJ, Maron MS, Wigle ED, Braunwald E, J Am Coll Cardiol 2009 54 191 200 10.1016/j.jacc.2008.11.069 19589431
78. Cardiovascular magnetic resonance in cardiac amyloidosis. Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, Sheppard MN, Poole-Wilson PA, Hawkins PN, Pennell DJ, Circulation 2005 111 186 193 10.1161/01.CIR. 0000152819.97857.9D 15630027
79. Prognostic impact of T2-weighted CMR imaging for cardiac amyloidosis. Wassmuth R, Abdel-Aty H, Bohl S, Schulz-Menger J, Eur Radiol 2011 21 1643 1650 10.1007/s00330-011-2109-3 21720941
80. Diagnostic and prognostic utility of cardiovascular magnetic resonance imaging in light-chain cardiac amyloidosis. Ruberg FL, Appelbaum E, Davidoff R, Ozonoff A, Kissinger KV, Harrigan C, Skinner M, Manning WJ, Am J Cardiol 2009 103 544 549 10.1016/j.amjcard.2008.09.105 19195518
81. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, et al. JACC Cardiovasc Imaging 2010 3 155 164 10.1016/j.jcmg.2009.09.023 20159642
82. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U, J Am Coll Cardiol 2008 51 1022 1030 10.1016/j.jacc.2007.10.049 18325442
83. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ, J Cardiovasc Magn Reson 2008 10 54 10.1186/1532-429X-10-54 19032744
84. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey. Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, Hughes DA, Heart 2011 97 1957 1960 10.1136/heartjnl-2011-300364 21890869
85. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. De Cobelli F, Esposito A, Belloni E, Pieroni M, Perseghin G, Chimenti C, Frustaci A, Del Maschio A, AJR Am J Roentgenol 2009 192 97 W102 10.2214/AJR.08.1201 19234246
86. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ, J Cardiovasc Magn Reson 2006 8 479 482 10.1080/10976640600605002 16755835
87. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Imbriaco M, Pisani A, Spinelli L, Cuocolo A, Messalli G, Capuano E, Marmo M, Liuzzi R, Visciano B, Cianciaruso B, Salvatore M, Heart 2009 95 1103 1107 10.1136/hrt.2008.162800 19372091
88. Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy. Messalli G, Imbriaco M, Avitabile G, Russo R, Iodice D, Spinelli L, Dellegrottaglie S, Cademartiri F, Salvatore M, Pisani A, Radiol Med 2011 117 19 28 21744250
89. Truncations of titin causing dilated cardiomyopathy. Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, Conner L, DePalma SR, McDonough B, Sparks E, et al. N Engl J Med 2012 366 619 628 10.1056/ NEJMoa1110186 22335739
90. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, Pennell DJ, Circulation 2003 108 54 59 10.1161/01.CIR.0000078641.19365.4C 12821550
91. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, Sheppard MN, Poole-Wilson PA, Pennell DJ, J Am Coll Cardiol 2006 48 1977 1985 10.1016/j.jacc.2006.07.049 17112987
92. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, Pribe R, Ehlermann P, Zugck C, Korosoglou G, et al. Heart 2011 97 727 732 10.1136/hrt.2010.205542 21097819
93. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, Lai S, Bluemke DA, Gerstenblith G, Marban E, et al. J Am Coll Cardiol 2008 51 2414 2421 10.1016/j.jacc.2008.03.018 18565399
94. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy. Schalla S, Bekkers SC, Dennert R, van Suylen RJ, Waltenberger J, Leiner T, Wildberger J, Crijns HJ, Heymans S, Eur J Heart Fail 2010 12 227 231 10.1093/eurjhf/hfq004 20156939
95. Clinical implication of adenosine-stress cardiac magnetic resonance imaging as potential gatekeeper prior to invasive examination in patients with AHA/ACC class II indication for coronary angiography. Pilz G, Bernhardt P, Klos M, Ali E, Wild M, Hofling B, Clin Res Cardiol 2006 95 531 538 10.1007/s00392-006-0422-7 16897145
96. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, Calkins H, Corrado D, Cox MG, Daubert JP, et al. Eur Heart J 2010 31 806 814 10.1093/eurheartj/ehq025 20172912
97. Impact of revised Task Force Criteria: distinguishing the athlete's heart from ARVC/D using cardiac magnetic resonance imaging. Luijkx T, Velthuis BK, Prakken NH, Cox MG, Bots ML, Mali WP, Hauer RN, Cramer MJ, Eur J Cardiovasc Prev Rehabil 2011 19 885 891
98. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: comparison with task force criteria and genotype. Sen-Chowdhry S, Prasad SK, Syrris P, Wage R, Ward D, Merrifield R, Smith GC, Firmin DN, Pennell DJ, McKenna WJ, J Am Coll Cardiol 2006 48 2132 2140 10.1016/j.jacc.2006.07.045 17113003
99. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. Sen-Chowdhry S, Syrris P, Prasad SK, Hughes SE, Merrifield R, Ward D, Pennell DJ, McKenna WJ, J Am Coll Cardiol 2008 52 2175 2187 10.1016/j.jacc.2008. 09.019 19095136
100. Noninvasive detection of myocardial fibrosis in arrhythmogenic right ventricular cardiomyopathy using delayed-enhancement magnetic resonance imaging. Tandri H, Saranathan M, Rodriguez ER, Martinez C, Bomma C, Nasir K, Rosen B, Lima JA, Calkins H, Bluemke DA, J Am Coll Cardiol 2005 45 98 103 10.1016/j.jacc.2004.09.053 15629382
101. Impact of the Revision of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia Task Force Criteria on Its Prevalence by CMR Criteria. Vermes E, Strohm O, Otmani A, Childs H, Duff H, Friedrich MG, JACC Cardiovasc Imaging 2011 4 282 287 10.1016/j.jcmg.2011.01.005 21414577
102. Use of cardiovascular magnetic resonance imaging in acute coronary syndromes. Lockie T, Nagel E, Redwood S, Plein S, Circulation 2009 119 1671 1681 10.1161/CIRCULATIONAHA.108.816512 19332480
103. Cardiac magnetic resonance imaging for the diagnosis of patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Gerbaud E, Harcaut E, Coste P, Erickson M, Lederlin M, Labeque JN, Perron JM, Cochet H, Santos PD, Durrieu-Jais C, et al. Int J Cardiovasc Imaging 2011 28 783 794 21538065
104. Cardiac magnetic resonance with T2-weighted imaging improves detection of patients with acute coronary syndrome in the emergency department. Cury RC, Shash K, Nagurney JT, Rosito G, Shapiro MD, Nomura CH, Abbara S, Bamberg F, Ferencik M, Schmidt EJ, et al. Circulation 2008 118 837 844 10.1161/ CIRCULATIONAHA.107.740597 18678772
105. Cardiac magnetic resonance monitors reversible and irreversible myocardial injury in myocarditis. Zagrosek A, Abdel-Aty H, Boye P, Wassmuth R, Messroghli D, Utz W, Rudolph A, Bohl S, Dietz R, Schulz-Menger J, JACC Cardiovasc Imaging 2009 2 131 138 10.1016/j.jcmg.2008.09.014 19356545
106. Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, et al. Circulation 2006 114 1581 1590 10.1161/CIRCULATIONAHA.105.606509 17015795
107. The role of cardiovascular magnetic resonance in patients presenting with chest pain, raised troponin, and unobstructed coronary arteries. Assomull RG, Lyne JC, Keenan N, Gulati A, Bunce NH, Davies SW, Pennell DJ, Prasad SK, Eur Heart J 2007 28 1242 1249 10.1093/eurheartj/ehm113 17478458
108. Long-term follow-up of patients with acute myocarditis by magnetic resonance imaging. Wagner A, Schulz-Menger J, Dietz R, Friedrich MG, MAGMA 2003 16 17 20 10.1007/s10334-003-0007-7 12695882
109. Differential diagnosis of suspected apical ballooning syndrome using contrast-enhanced magnetic resonance imaging. Eitel I, Behrendt F, Schindler K, Kivelitz D, Gutberlet M, Schuler G, Thiele H, Eur Heart J 2008 29 2651 2659 10.1093/eurheartj/ehn433 18820322
110. Immunohistological basis of the late gadolinium enhancement phenomenon in tako-tsubo cardiomyopathy. Rolf A, Nef HM, Mollmann H, Troidl C, Voss S, Conradi G, Rixe J, Steiger H, Beiring K, Hamm CW, Dill T, Eur Heart J 2009 30 1635 1642 10.1093/eurheartj/ehp140 19389788
111. Occurrence of late gadolinium enhancement in ventricular ballooning or Tako-Tsubo syndrome: increased wall stress should not be overlooked. Alter P, Rupp H, Eur Heart J 2009 30 2948 2949 author reply 2949 10.1093/eurheartj/ehp451 19889650
112. Clinical characteristics and cardiovascular magnetic resonance findings in stress (takotsubo) cardiomyopathy. Eitel I, von Knobelsdorff-Brenkenhoff F, Bernhardt P, Carbone I, Muellerleile K, Aldrovandi A, Francone M, Desch S, Gutberlet M, Strohm O, et al. JAMA 2011 306 277 286 10.1001/jama.2011.992 21771988
113. MRI of cardiac sarcoidosis: basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. Ichinose A, Otani H, Oikawa M, Takase K, Saito H, Shimokawa H, Takahashi S, AJR Am J Roentgenol 2008 191 862 869 10.2214/AJR.07.3089 18716120
114. Detection of myocardial damage in patients with sarcoidosis. Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA, Meine TJ, White JB, Elliott MD, Kim HW, et al. Circulation 2009 120 1969 1977 10.1161/
115. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, Crijns HJ, J Am Coll Cardiol 2005 45 1683 1690 10.1016/j.jacc.2005.01.047 15893188
116. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Sharma S, Curr Opin Pulm Med 2009 15 507 512 10.1097/MCP.0b013e32832ea4c7 19542892
117. Cardiac magnetic resonance imaging in the evaluation of cardiac sarcoidosis: an Australian single-centre experience. Manins V, Habersberger J, Pfluger H, Taylor AJ, Intern Med J 2009 39 77 82 10.1111/j.1445-5994.2008.01674. x 18771431
118. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM, Burke MC, Garrity ER, Hogarth DK, Archer SL, et al. Eur J Heart Fail 2011 13 1231 1237 10.1093/eurjhf/hfr099 21810833
119. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M, Inoue S, Katoh H, Murakami Y, Ishibashi Y, Maruyama R, Am J Med 2001 110 520 527 10.1016/S0002-9343(01) 00677-5 11343665
120. Left ventricular non-compaction: insights from cardiovascular magnetic resonance imaging. Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, Watkins H, Neubauer S, J Am Coll Cardiol 2005 46 101 105 10.1016/j.jacc.2005.03.045 15992642
121. Myocardial fibrosis in isolated left ventricular non-compaction and its relation to disease severity. Nucifora G, Aquaro GD, Pingitore A, Masci PG, Lombardi M, Eur J Heart Fail 2011 13 170 176 10.1093/eurjhf/hfq222 21208941
122. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ, J Cardiovasc Magn Reson 2008 10 42 10.1186/1532-429X-10-42 18817553
123. On T2* magnetic resonance and cardiac iron. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, et al. Circulation 2011 123 1519 1528 10.1161/CIRCULATIONAHA.110. 007641 21444881
124. Low prevalence of fibrosis in thalassemia major assessed by late gadolinium enhancement cardiovascular magnetic resonance. Kirk P, Carpenter JP, Tanner MA, Pennell DJ, J Cardiovasc Magn Reson 2011 13 8 10.1186/1532-429X-13-8 21241474
125. Diagnostic applicability of magnetic resonance imaging in assessing human cardiac allograft rejection. Wisenberg G, Pflugfelder PW, Kostuk WJ, McKenzie FN, Prato FS, Am J Cardiol 1987 60 130 136 10.1016/0002-9149(87)90999-4 3300244
126. Detection and prediction of acute heart transplant rejection with the myocardial T2 determination provided by a black-blood magnetic resonance imaging sequence. Marie PY, Angioi M, Carteaux JP, Escanye JM, Mattei S, Tzvetanov K, Claudon O, Hassan N, Danchin N, Karcher G, et al. J Am Coll Cardiol 2001 37 825 831 10.1016/S0735-1097(00)01196-7 11693758
127. Prevalence of different gadolinium enhancement patterns in patients after heart transplantation. Steen H, Merten C, Refle S, Klingenberg R, Dengler T, Giannitsis E, Katus HA, J Am Coll Cardiol 2008 52 1160 1167 10.1016/j.jacc.2008. 05.059 18804744
128. Myocardial delayed enhancement by magnetic resonance imaging in patients with Chagas' disease: a marker of disease severity. Rochitte CE, Oliveira PF, Andrade JM, Ianni BM, Parga JR, Avila LF, Kalil-Filho R, Mady C, Meneghetti JC, Lima JA, Ramires JA, J Am Coll Cardiol 2005 46 1553 1558 10.1016/j.jacc.2005.06. 067 16226184
129. de Oliveira Junior AC, Siqueira-Batista R, Marchiori E, Uellendahl M, de Lourdes Higuchi M: Cardiac magnetic resonance in Chagas' disease. Rochitte CE, Nacif MS, Artif Organs 2007 31 259 267 10.1111/j.1525-1594.2007.00373.x 17437493
130. Doxorubicin-induced cardiomyopathy. Singal PK, Iliskovic N, N Engl J Med 1998 339 900 905 10.1056/NEJM199809243391307 9744975
131. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS, J Cardiovasc Magn Reson 2008 10 5 10.1186/1532-429X-10-5 18272009
132. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, et al. J Am Coll Cardiol 2011 57 2263 2270 10.1016/j.jacc.2010.11.063 21616287
133. Late gadolinium enhancement in left ventricular dysfunction after trastuzumab. Wassmuth R, Schulz-Menger J, J Am Coll Cardiol 2011 58 2697 2698 author reply 2699-2700 10.1016/j.jacc.2011.06.071 22152960
134. Lessons Learned from the European Cardiovascular Magnetic Resonance (EuroCMR) Registry Pilot Phase. Bruder O, Wagner A, Mahrholdt H, Curr Cardiovasc Imaging Rep 2010 3 171 174 10.1007/s12410-010-9016-x 20461126
135. Clinical cardiac magnetic resonance spectroscopy. Holloway CJ, Suttie J, Dass S, Neubauer S, Prog Cardiovasc Dis 2011 54 320 327 10.1016/j.pcad.2011.08. 002 22014498
136. Magnetic resonance spectroscopy in myocardial disease. Hudsmith LE, Neubauer S, JACC Cardiovasc Imaging 2009 2 87 96 10.1016/j.jcmg.2008.08.005 19356540
137. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K, Circulation 1997 96 2190 2196 10.1161/01.CIR.96.7.2190 9337189
138. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, Scifo P, Calori G, Del Maschio A, Margonato A, Eur Heart J 2006 27 942 948 16510466
139. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. Korosoglou G, Humpert PM, Ahrens J, Oikonomou D, Osman NF, Gitsioudis G, Buss SJ, Steen H, Schnackenburg B, Bierhaus A, et al. J Magn Reson Imaging 2012 34 804 811
140. Patients with syndrome x have normal transmural myocardial perfusion and oxygenation: a 3-T cardiovascular magnetic resonance imaging study. Karamitsos TD, Arnold JR, Pegg TJ, Francis JM, Birks J, Jerosch-Herold M, Neubauer S, Selvanayagam JB, Circ Cardiovasc Imaging 2012 5 194 200 10.1161/CIRCIMAGING.111. 969667 22322441
141. Relationship between regional myocardial oxygenation and perfusion in patients with coronary artery disease: insights from cardiovascular magnetic resonance and positron emission tomography. Karamitsos TD, Leccisotti L, Arnold JR, Recio-Mayoral A, Bhamra-Ariza P, Howells RK, Searle N, Robson MD, Rimoldi OE, Camici PG, et al. Circ Cardiovasc Imaging 2010 3 32 40 10.1161/CIRCIMAGING. 109.860148 19920032
142. Navigator-gated 3D blood oxygen level-dependent CMR at 3.0-T for detection of stress-induced myocardial ischemic reactions. Jahnke C, Gebker R, Manka R, Schnackenburg B, Fleck E, Paetsch I, JACC Cardiovasc, Imaging 2010 3 375 384 10.1016/j.jcmg.2009.12.008
143. Quantification of regional myocardial oxygenation by magnetic resonance imaging: validation with positron emission tomography. McCommis KS, Goldstein TA, Abendschein DR, Herrero P, Misselwitz B, Gropler RJ, Zheng J, Circ Cardiovasc Imaging 2010 3 41 46 10.1161/CIRCIMAGING.109.897546 19933371
144. Oxygenation-sensitive CMR for assessing vasodilator-induced changes of myocardial oxygenation. Vohringer M, Flewitt JA, Green JD, Dharmakumar R, Wang J, Tyberg JV, Friedrich MG, J Cardiovasc Magn Reson 2010 12 20 10.1186/1532-429X-12-20 20356402
145. Blood oxygen level-dependent magnetic resonance imaging in patients with stress-induced angina. Friedrich MG, Niendorf T, Schulz-Menger J, Gross CM, Dietz R, Circulation 2003 108 2219 2223 10.1161/01.CIR.0000095271.08248.EA 14557359